GSK plc - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US37733W2044

SecurityGSK / GSK plc - Depositary Receipt (Common Stock)
InstitutionNatixis Advisors, L.p.
Latest Disclosed Ownership254,716 shares
Latest Disclosed Value $ 14,058
Natixis Advisors, L.p. reports 27.48% increase in ownership of GSK / GSK plc - Depositary Receipt (Common Stock)

On May 13, 2026 - Natixis Advisors, L.p. filed a 13F-HR form disclosing ownership of 254,716 shares of GSK plc - Depositary Receipt (Common Stock) (US:GSK) valued at $14,057,776 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 199,807 shares of GSK plc - Depositary Receipt (Common Stock). This represents a change in shares of 27.48% during the quarter. The current value of the position is $13,122,968 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F GSK SPONSORED ADR 37733W204 254,716 54,909 27.48 14 55.56 0.0196
2026-02-10 2025-12-31 13F GSK SPONSORED ADR 37733W204 199,807 -153,192 -43.40 10 -40.00 0.0139
2025-11-13 2025-09-30 13F GSK SPONSORED ADR 37733W204 352,999 -1,992 -0.56 15 15.38 0.0222
2025-08-13 2025-06-30 13F GSK SPONSORED ADR 37733W204 354,991 -12,054 -3.28 14 -7.14 0.0216
2025-05-08 2025-03-31 13F GSK SPONSORED ADR 37733W204 367,045 23,711 6.91 14 27.27 0.0263
2025-02-10 2024-12-31 13F GSK SPONSORED ADR 37733W204 343,334 -157,161 -31.40 12 -45.00 0.0217
2024-11-06 2024-09-30 13F GSK SPONSORED ADR 37733W204 500,495 83,433 20.00 20 25.00 0.0399
2024-08-01 2024-06-30 13F GSK SPONSORED ADR 37733W204 417,062 39,346 10.42 16 0.00 0.0349
2024-04-25 2024-03-31 13F GSK SPONSORED ADR 37733W204 377,716 52,040 15.98 16 33.33 0.0372
2024-02-06 2023-12-31 13F GSK SPONSORED ADR 37733W204 325,676 31,566 10.73 12 20.00 0.0318
2023-11-13 2023-09-30 13F GSK SP ADR REP B NVT 37733W204 294,110 51,922 21.44 11 25.00 0.0326
2023-08-15 2023-06-30 13F GSK SP ADR REP B NVT 37733W204 242,188 31,342 14.86 9 14.29 0.0267
2023-05-11 2023-03-31 13F GSK SPONSORED ADR 37733W204 210,846 43,011 25.63 8 40.00 0.0258
2023-01-27 2022-12-31 13F GSK SPONSORED ADR 37733W204 167,835 -54,892 -24.65 6 -99.92 0.0223
2022-11-14 2022-09-30 13F GSK SP ADR REP B NVT 37733W204 222,727 222,727 6,555 0.0277
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.